ESMO attendees were treated to the results from 2 fantastic studies from Spain investigating genomic signatures in sinonasal cancers (SNCs), neuroendocrine tumours (NETs) and neuroendocrine carcinomas (NECs).

The responses to the Senate Inquiry into equitable access to diagnosis and treatment for individuals with rare and less common cancers are now available to read on the Parliament of Australia website.

Rare Cancers Australia and Canteen have launched their follow up report on rare cancers, Counting the cost: How we can assess the true value of investing in cancer treatment.

Australians with leiomyosarcoma or liposarcoma will now be able to access the novel anti-tumour agent Yondelis (trabectedin) at a cost of approximately $30 per script following its PBS listing in August 2023.